Sidley advised Beijing Advaccine Biotechnology Co., Ltd. (Advaccine) in entering into a collaboration and license agreement with INOVIO Pharmaceuticals Inc. (NASDAQ: INO) (INOVIO) for COVID-19 DNA vaccine candidate INO-4800.
Advaccine is an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic. INOVIO is a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer.
Under the collaboration and license agreement, Advaccine will have the exclusive right to develop, manufacture, and commercialize INO-4800 within Greater China, inclusive of Mainland China, Hong Kong, Macao, and Taiwan. Advaccine will license its plasmid manufacturing process for use with INO-4800 and other INOVIO pipeline product candidates to INOVIO. Additionally, Advaccine will provide its clinical data to INOVIO in support of INOVIO’s global INO-4800 regulatory filings, and INOVIO will provide its INO-4800 clinical data for Advaccine to incorporate into its marketing applications in Greater China.
The Sidley team included senior counsel Chen Yang, with support from others.
Sidley is a multidisciplinary one-stop service shop in the market for life sciences clients. We advise clients across different stages of their life cycles, ranging from formation, corporate governance, and compliance operations in the startup period, to collaboration, licensing, commercialization, and filing in the business development phase, to initial public offering, refinancing, and bonds/notes issues in the raising capital stage, to domestic and overseas mergers and acquisitions, asset restructuring, equity incentive plans, and privatization transactions when clients expand their businesses.